Observation of the curative effect of irinotecan HCL trihydrate combination with cisplatin in treatment of non-small cell lung cancer
10.3760/cma.j.issn.1008-6706.2011.09.014
- VernacularTitle:伊利替康联合顺铂治疗晚期非小细胞肺癌的疗效观察
- Author:
Jianliang WU
;
Ran YAO
;
Xiaoxia LI
- Publication Type:Journal Article
- Keywords:
Carcinoma,Non-small-cell Lung;
Irinoteean HCL trihydrate;
Cisplatin;
Etoposide
- From:
Chinese Journal of Primary Medicine and Pharmacy
2011;18(9):1182-1184
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical curative effect of irinotecan HCL trihydrate combination with cisplatin in treatment of non.small-cell carcinoma(NSCC)by observing the clinical curative effect,adverse reactions and the improvement of the quality of life post therapy.Methods 120 patients with NSCC were divided into two groups.60 cases in control group were treated with cisplatin and topotecan while ifinotecan HCL tfihydrate combination with cisplatin chemotherapy for 60 case of patients in observation group.The curative effect and Kamtfsky point were observed.Results The effective rate of observation group was 56.7%,which was significantly higher than that of the control group(41.7%),and differences between the two groupswas statistically significant(P＜0.05).Average survival time for treatment group was(9.3±4.2)months that was longer than that of the control group[(7.2±3.2)months](P＜0.05).The result of Kamofsky classification standard after chemotherapy also indicated the same situation(P＜0.05).Conclusion Irinotecan HCL trihydrate combining with cisplatin in treatment of non-small cell lung cancer had a effective therapy result and could reduce the toxicity.as well as improving the quality of life of the patients.
